Research programme: chitosan-encapsulated inflammatory bowel disease therapeutics - Advancell
Alternative Names: ANs42Latest Information Update: 16 Jul 2016
At a glance
- Originator Advancell
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Ulcerative colitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in Spain
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ulcerative-colitis in Spain
- 20 Apr 2012 Preclinical trials in Crohn's disease in Spain (unspecified route)